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Abstract The CX3C chemokine, fractalkine (FKN, CX3CL1),
has multiple functions and exists as two distinct forms, a mem-
brane-anchored protein and a soluble chemotactic peptide that
cleaves from the cell surface FKN. In this study, we ¢rst dem-
onstrated the expression of FKN in tumor necrosis factor
(TNF)-K- and interleukin (IL)-4-stimulated human ¢broblasts.
The induction of FKN was observed for both forms. We also
demonstrated monocyte chemotactic activity in the culture
supernatant from the ¢broblasts stimulated with these cytokines.
These results suggest that TNF-K- and IL-4-stimulated ¢bro-
blasts may play an important role in accumulation of monocytes
at in£ammatory sites.
, 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
The tra⁄cking of leukocytes out of circulation and into
sites of in£ammation requires multiple steps including selec-
tin-dependent rolling and chemokine-induced arrest mediated
by integrins [1,2]. More than 50 chemokines have been iden-
ti¢ed to date, and these are subdivided into four subfamilies
on the basis of the number and spacing of the ¢rst two cys-
teine residues in a conserved cysteine structural motif : C, CC,
CXC and CX3C [3]. Di¡erent chemokine classes tend to ex-
hibit di¡erent ranges of leukocyte speci¢city. The sole member
of the CX3C subfamily, fractalkine (FKN, CX3CL1), has two
structural features that make it unique in the chemokine fam-
ily: a CX3C motif and an extended carboxy-terminus that
anchors it to the cell surface [4,5]. It is expressed on the sur-
face of endothelial cells, epithelial cells, dendritic cells and
neurons and is up-regulated by pro-in£ammatory cytokines
such as interleukin (IL)-1 and tumor necrosis factor (TNF)-
K [6^9]. Furthermore, FKN has multiple functions and exists
as two distinct forms, a membrane-anchored proadhesive pro-
tein (mFKN) and a soluble chemotactic peptide (sFKN) that
is released from the cell surface through proteolytic cleavage
at membrane-proximal regions by TNF-K-converting enzyme
(TACE), a member of the ADAM (disintegrin and metallo-
protease) family, and ADAM10 [4].
Both the adhesion and chemotactic properties of FKN are
mediated via a speci¢c G protein-coupled, seven-transmem-
brane domain receptor, V28, now termed CX3CR1 [10^12].
Surface expression of CX3CR1 has been demonstrated on NK
cells, QN T cells, CD8þ T cells, and CD4þ T cells equipped
with cytotoxic granules, monocytes, and mast cells [10,13^16].
CX3CR1 is capable of mediating both leukocyte migration
and adhesion. Firm adhesion is not inhibited by pertussis
toxin under static and physiological £ow conditions in mono-
cytes, T cells and NK cells [13]. Unlike other chemokine/G
protein-coupled receptor interactions that require signal trans-
duction and integrin activation for ¢rm cell adhesion, the
adhesive interaction between FKN and CX3CR1 is indepen-
dent of signal transduction and integrin function [13,14].
However, it has recently been demonstrated that FKN can
induce adhesion by up-regulating integrin avidity in a pertus-
sis toxin-sensitive manner [17].
Nasal polyposis is a chronic in£ammatory disease of the
nasal mucosa sometimes a¡ecting patients with allergy. The
polyp stroma is highly edematous, with a varying density of
in£ammatory cells and ¢broblasts [18]. In the airway, ¢bro-
blasts, which also include myo¢broblasts, produce collagen
and have been shown to produce speci¢c cytokines that may
attract in£ammatory cells to the airway and perpetuate the
in£ammatory and ¢brotic processes [19,20].
The purpose of this study was to examine the expression of
FKN in human ¢broblasts established from human nasal pol-
yp biopsy specimens because of the putative importance of
TNF-K and IL-4 in controlling allergic in£ammation. We
have also analyzed the induction of FKN in lung- and skin-
derived ¢broblasts.
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2. Materials and methods
2.1. Reagents
Recombinant TNF-K, interferon (IFN)-Q, IL-4 and IL-13 were pur-
chased from RpD Systems (Minneapolis, MN, USA). Monoclonal
antibodies (mAb) against FKN (1F3-1 and 3A5-2) were prepared in
our laboratory (Kan Research Institute). Polyclonal antibody against
FKN was purchased from RpD Systems. Polyclonal antibody against
CX3CR1 was purchased from Torrey Pines Biolabs (Houston, TX,
USA).
2.2. Cell cultures
Human nasal ¢broblasts were established from nasal polyp biopsy
specimens. Brie£y, single cells isolated from nasal polyp specimens
were washed with phosphate-bu¡ered saline (PBS), and then cultured
in RPMI 1640 medium containing 10% heat-inactivated fetal calf
serum (FCS; JRH Bioscience, Lenexa, KS, USA), 100 U/ml penicil-
lin^100 Wg/ml streptomycin (Gibco BRL, Grand Island, NY, USA)
and 3 Wg/ml amphotericin B (Sigma, St. Louis, MO, USA). The cells
were incubated at 37‡C in a humidi¢ed incubator containing 5% CO2
in air. The cells were used between passages 3 and 10 for analysis of
FKN induction.
A human fetal lung ¢broblast line, MRC-5-30, was purchased from
Health Science Research Resources Bank (Osaka, Japan) and cultured
in Eagle’s minimal essential medium (Gibco BRL) with 10% FCS,
penicillin^streptomycin and amphotericin B. The cells were used be-
tween passages 31 and 34.
Normal human dermal ¢broblasts (adult skin) were obtained from
Clonetics (Walkersville, MD, USA) and cultured in Fibroblast Basal
Medium (Clonetics) with 2% fetal bovine serum, 1 Wg/ml human re-
combinant ¢broblast growth factor, 5 Wg/ml insulin, 50 Wg/ml genta-
micin and 50 Wg/ml amphotericin B (Clonetics).
2.3. Cytokine stimulation of ¢broblasts
For cytokine stimulation, ¢broblasts were cultured in 6-well or 48-
well culture plates (Becton Dickinson, Franklin Lakes, NJ, USA).
They were grown to approximately 80% con£uence, and then the
culture medium was replaced with Dulbecco’s modi¢ed Eagle’s me-
dium/Ham’s F12 medium (Gibco BRL) without FCS in the presence
of various cytokines.
2.4. Relative quantitation of mRNA by reverse transcription polymerase
chain reaction (RT-PCR)
Nasal ¢broblasts were cultured with TNF-K (50 ng/ml) and IL-4 (10
ng/ml) alone or in combination for 12^48 h. Total RNA was extracted
with an RNeasy kit (Qiagen, Valencia, CA, USA) according to the
manufacturer’s instructions. First-strand cDNA syntheses were per-
formed using a Ready-To-Go kit (Amersham Pharmacia Biotech,
Uppsala, Sweden). The PCR conditions were optimized empirically
using AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster
City, CA, USA) and GeneAmp PCR system 9600 (Applied Biosys-
tems). Forward and reverse oligo primers for FKN (5P-ATG GCT
CCG ATA TCT CTG TCG T-3P for sense and 5P-AAA AGC TCC
GTG CCC ACA-3P for antisense) and GAPDH (5P-GTC TTC ACC
ACC ATG GAG AAG GCT-3P for sense and 5P-CAT GCC AGT
GAG CTT CCC GTT CA-3P for antisense) were designed based on
the published sequences of each mRNA. The ampli¢ed fragments of
FKN and GAPDH were 557 bp and 393 bp, respectively, as expected.
DNA polymerase was activated by preheating (1 min at 94‡C). Then
ampli¢cation was performed for 37 cycles of denaturation (1 min at
94‡C), annealing (1 min at 55‡C), and elongation (2 min at 72‡C)
followed by ¢nal elongation (10 min at 72‡C). PCR products were
electrophoresed through a 2% agarose gel and visualized with ethid-
ium bromide. For semi-quantitative RT-PCR, the relative band inten-
sities were analyzed with an Agilent 2100 Bioanalyzer (Agilent Tech-
nologies, Waldbronn, Germany).
2.5. Flow cytometric analysis
Nasal ¢broblasts were cultured with TNF-K (50 ng/ml) and IL-4 (10
ng/ml) alone or in combination for 72 h and were detached with a
non-enzymatic cell dissociation solution (Gibco BRL). The cells were
then incubated with anti-human FKN (1F3-1) mAb in the presence of
human IgG (50 mg/ml) for 30 min at 4‡C. Fluorescein isothiocyanate-
labeled goat anti-mouse Ig Ab (Becton Dickinson, San Jose, CA,
USA) was then applied for 20 min at 4‡C. As a control, cells were
incubated under similar conditions with mouse IgG1 (clone MOPC
21; Sigma). The cells were ¢xed with 4% formaldehyde in PBS and
were analyzed on a FACScan (Becton Dickinson). The £uorescence
intensity was determined for 10 000 cells per sample using the CELL-
Quest software (Becton Dickinson).
2.6. Enzyme-linked immunosorbent assay (ELISA) for FKN
For quanti¢cation of sFKN, cell culture supernatants were col-
lected and stored frozen at 380‡C until use. In some experiments,
the cell culture supernatant was concentrated with Ultrafree-MC cen-
trifugal ¢lter units (Millipore, Bedford, MA, USA). To determine
total FKN in nasal ¢broblasts, cells were solubilized with ice-cold
lysis bu¡er containing 0.2% NP-40 and protease inhibitor cocktail
tablets (Roche, Mannheim, Germany), centrifuged, and the soluble
extract was prepared. FKN concentrations were analyzed by sand-
wich-type ELISA. Brie£y, a 96-well plate (Nunc, Roskilde, Denmark)
was coated with 5 Wg/ml of anti-human FKN mAb (3A5-2) overnight
at 4‡C. The plate was washed and then blocked with blocking solution
(Boehringer, Mannheim, Germany) for 1 h at room temperature.
Samples or recombinant human FKN (RpD Systems) as a standard
were added to the wells, and the plate was incubated at 4‡C overnight.
After washing with 0.1% Brij-PBS, 0.25 ng/ml of biotinylated poly-
clonal anti-FKN Ab (RpD Systems) was added, and the plate was
incubated for 3 h at room temperature. After washing, 100 Wl of
streptavidin-horseradish peroxidase (Gibco BRL) was added, and
the plate was incubated for 30 min at room temperature. The wells
were developed with the TMB microwell substrate system (Kirkegaard
and Perry Laboratories, Gaithersburg, MD, USA). The reaction was
stopped with 1 M H3PO4, and the absorbance was read at 490 nm
with a microtiter ELISA reader (MR5000, Dynatech Laboratories,
Chantilly, VA, USA). Data were analyzed with the Biolinx 2.10 pro-
gram (Dynatech Laboratories), and the concentration of FKN was
calculated by linear regression analysis from the standard curves.
2.7. Chemotaxis assay
The biological activity of FKN in the culture supernatant of cyto-
kine-stimulated ¢broblasts was assessed by a chemotaxis assay using
human monocytes. The monocytes were separated by the cold aggre-
gation method [21].
Brie£y, mononuclear cells were isolated from the peripheral blood
of normal healthy volunteers using lymphocyte separation medium
(ICN Biomedicals, Aurora, OH, USA). The mononuclear cells at
1U107 cell/ml in RPMI 1640 containing 10% FCS were then agitated
gently for 1 h at 4‡C and aggregated monocytes were collected. The
purity of the monocytes was determined by £ow cytometry using anti-
human CD14 Ab and was more than 80%. For the chemotaxis assay,
48-well plates assembled with Boyden chambers (5-Wm pore size poly-
carbonate membranes) were used. Brie£y, 29 Wl of cell culture super-
natants of the ¢broblasts stimulated with TNF-K plus IL-4 for 96 h
were placed in triplicate in the lower chamber. After assembly of the
Boyden chambers, 50-Wl suspensions of human monocytes (50 000
cells) in RPMI 1640 containing 0.1% bovine serum albumin (BSA)
were placed in the upper chamber. The chambers were then incubated
in a humidi¢ed CO2 incubator at 37‡C for 30 min. After the incuba-
tion, the ¢lters were recovered, non-migrating cells were removed
from the upper surface by washing with PBS, and then the cells
that had migrated across the membrane were ¢xed, and stained by
Di¡-Quick. In some experiments, human monocytes were preincu-
bated with 10 Wg/ml of puri¢ed rabbit anti-human CX3CR1 Ab or
rabbit IgG as a control, and the chemotactic activity was measured as
described above. Migrated monocytes were counted in three random
high-power ¢elds by light microscopy, and speci¢c chemotactic activ-
ity was expressed as the net percentage after subtraction of sponta-
neous migration in fresh culture medium containing TNF-K and IL-4.
2.8. Statistical analysis
Data are presented as the meanTS.E.M. Statistical signi¢cance was
determined by the paired Student’s t-test and P6 0.05 was considered
signi¢cant.
3. Results
3.1. Detection of FKN mRNA by RT-PCR
We ¢rst analyzed the mRNA levels of FKN in human nasal
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¢broblasts from patients with or without allergy in the pres-
ence of TNF-K and/or IL-4 by RT-PCR (Fig. 1A). The FKN
transcript in these ¢broblasts was up-regulated in the presence
of TNF-K. In contrast, expression of FKN mRNA was not
detected in the cells exposed to IL-4 alone. We observed sim-
ilar induction of FKN mRNA in nasal ¢broblasts derived
both from patients with and without allergy. We also deter-
mined the time kinetics of the expression of FKN mRNA
after stimulation with these cytokines. The FKN mRNA
was signi¢cantly up-regulated by TNF-K in a time-dependent
fashion, and reached peak levels within the ¢rst 12 h and
decreased by 24 h (Fig. 1B). In addition, the combined stim-
ulation with TNF-K and IL-4 showed continuous enhance-
ment of the FKN mRNA level.
3.2. Detection of mFKN on the cell surface
We next examined the expression of mFKN protein on the
cell surface of human nasal ¢broblasts in the presence of
cytokines by £ow cytometric analysis using a FKN-speci¢c
mAb (1F3-1). The mFKN expression on the surface of human
nasal ¢broblasts was up-regulated by TNF-K for 72 h (Fig. 2).
In addition, IL-4 enhanced the expression of mFKN that was
induced by TNF-K.
3.3. Detection of FKN protein
We performed quantitative analysis of the induction of the
two forms of FKN proteins, i.e. sFKN in the cell culture
supernatant and mFKN on the cell surface. Therefore, an
ELISA for human FKN was developed using a mAb and a
polyclonal Ab, as described in Section 2. We determined the
concentration of sFKN in the supernatant from the ¢bro-
blasts in the presence of cytokines at various time points
(Fig. 3A,B). We detected the induction of sFKN in the super-
natant from TNF-K-stimulated ¢broblasts although IL-4 did
not a¡ect the induction. The combined stimulation with TNF-
K and IL-4 dramatically showed synergistic enhancement of
sFKN protein at 72^96 h (Fig. 3A). In contrast, IL-13 inhib-
ited the induction of sFKN in the supernatant from IFN-Q-
stimulated ¢broblasts (Fig. 3B). We also determined the dose
dependence of TNF-K and IL-4 in the induction of sFKN
from nasal ¢broblasts cultured with these cytokines (Fig.
3C). The induction of sFKN was observed synergistically
with IL-4 in a dose-dependent fashion.
We also tested the induction of sFKN from human ¢bro-
blasts derived from di¡erent tissues (Fig. 3D). The sFKN
protein was detected not only from nasal ¢broblasts but
also from lung-derived (MRC-5-30) and skin-derived
(NHDF7555) ¢broblasts in the presence of the cytokines.
To evaluate whether production of sFKN accompanied the
expression of intracellular and membrane-anchored FKN, we
determined the total FKN in the cells. The amounts of intra-
cellular FKN, including mFKN, in nasal ¢broblasts was sig-
ni¢cantly up-regulated in the presence of TNF-K in a time-
dependent fashion, and reached peak levels within the ¢rst
72 h of stimulation (Fig. 4). IL-4 markedly enhanced the
TNF-K-induced FKN in whole cells.
3.4. Chemotactic activity of sFKN derived from ¢broblasts
Finally, we tested the chemotactic activity of sFKN derived
from the cytokine-stimulated nasal ¢broblasts. Human mono-
cytes express a receptor for FKN, CX3CR1, as described
above [10]. Therefore, we assessed the chemotactic activity
using human monocytes from peripheral blood (Fig. 5).
Monocyte chemotaxis was observed in the supernatant de-
rived from the TNF-K- and IL-4-stimulated ¢broblasts.
Also, 56.2% of the chemotactic activity was suppressed by
anti-CX3CR1 Ab (10 Wg/ml).
4. Discussion
In this study, we provide the ¢rst evidence that the expres-
sion of FKN is up-regulated by TNF-K in human ¢broblasts.
In this regard, previous studies determined that FKN was
primarily expressed by neurons [6,22,23] and endothelial cells
[8,10]. As far as ¢broblasts are concerned, FKN expression
was reported only for synovial tissue from patients with rheu-
matoid arthritis [24]. FKN was initially described as being
Fig. 1. Expression of FKN mRNA in human nasal ¢broblasts. A:
Cells from patients with or without allergy were incubated with
TNF-K (50 ng/ml) and/or IL-4 (10 ng/ml) for 12 h. FKN mRNA
was detected by RT-PCR. For semi-quantitative analysis, RT-PCR
products of FKN transcripts were analyzed with an Agilent 2100
Bioanalyzer. The vertical axis indicates the band intensities of FKN
corrected for GAPDH. Each RT-PCR analysis is representative of
at least three di¡erent experiments. B: The time kinetics of FKN
expression was determined up to 48 h by RT-PCR.
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expressed on IL-1L- and TNF-K-activated endothelial cells
and having a wide mRNA distribution in human [4] and mu-
rine tissues [5]. In this experiment, it is interesting that TNF-K
induced FKN in human ¢broblasts, which was synergistically
up-regulated by IL-4. Recently, Fraticelli et al. reported that
IFN-Q and TNF-K induced FKN expression on vascular en-
dothelial cells. In contrast, IL-4 and IL-13 suppressed this
induction in the endothelial cells [25]. Our results support
the induction of FKN in IFN-Q-stimulated ¢broblasts in their
¢nding. However, IL-4 synergistically enhanced TNF-K-in-
duced FKN in human ¢broblasts. A similar IL-4 synergistic
e¡ect was reported for TNF-K-induced eotaxin in human der-
mal ¢broblasts [26]. Furthermore, a recent study demon-
strated that both IL-4 and TNF-K induce eotaxin expression
at the level of transcription via a STAT6-mediated pathway
[27]. Presumably this di¡erent e¡ect of IL-4 is caused by the
di¡erence of characteristics between vascular endothelial cells
and ¢broblasts.
On the cell surface, the two peaks of FKN expression dem-
onstrate a biphasic population upon stimulation, where only a
subpopulation up-regulate FKN. This in itself is an extremely
interesting observation and may demonstrate the heterogene-
ity of ¢broblast populations, and their complex nature in
regulating immune function. One possibility is that FKN pro-
duction may be a product of this subpopulation only. Future
work should include isolation and characterization of this
population.
The expression of FKN mRNA reached a peak within the
¢rst 12 h. sFKN in the cell culture supernatant increased
rapidly during 72^96 h, although the expression of intracellu-
Fig. 2. Expression of mFKN on the cell surface of human nasal ¢broblasts. mFKN was detected by £ow cytometry. Cells were incubated with
TNF-K (50 ng/ml) and/or IL-4 (10 ng/ml) for 72 h. Each histogram is representative of at least three di¡erent experiments.
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lar FKN and mFKN peaked within the ¢rst 72 h and grad-
ually decreased in the following 24 h. These results indicate
that the extracellular domain of FKN undergoes proteolytic
cleavage and is released from the cell surface into the sur-
rounding £uid phase mainly during 72^96 h after stimulation.
FKN can be shed after extracellular proteolysis at a mem-
Fig. 3. Induction of sFKN in the culture supernatant from human nasal ¢broblasts. A: Cells were incubated with TNF-K (50 ng/ml) and/or
IL-4 (10 ng/ml) for 24^96 h. sFKN in the culture supernatant was detected by ELISA. *P6 0.05. B: Cells were incubated with IFN-Q (10 ng/
ml) and/or IL-13 (10 ng/ml) for 24^96 h. sFKN in the culture supernatant was detected by ELISA. *P6 0.05. C: Dose dependence of TNF-K
(0.5^50 ng/ml) and IL-4 (0.1^10 ng/ml) in the induction of sFKN. Cells were cultured with TNF-K and/or IL-4 for 72 h. *P6 0.05. D: Induc-
tion of sFKN in the culture supernatant from human fetal lung-derived ¢broblasts (MRC-5-30) and human skin-derived ¢broblasts
(NHDF7555). These ¢broblasts were incubated with TNF-K (50 ng/ml) and/or IL-4 (10 ng/ml) for 72 h. *P6 0.05.
Fig. 4. Induction of FKN protein in the cell lysate of human nasal
¢broblasts. Cells were incubated with TNF-K (50 ng/ml) and/or IL-
4 (10 ng/ml) for 24^96 h. FKN in the cell lysate was detected by
ELISA. *P6 0.05.
Fig. 5. Monocyte chemotaxis was observed in the supernatant de-
rived from the TNF-K- and IL-4-stimulated ¢broblasts with Boyden
chambers. Monocytes (50 000 cells in RPMI 1640 containing 0.1%
BSA) were seeded in each well and allowed to migrate at 37‡C for
30 min. In inhibition assays the cells were incubated with 10 Wg/ml
of puri¢ed rabbit anti-human CX3CR1 Ab or rabbit IgG as a con-
trol before seeding in each well. Cells were counted in three random
high-power ¢elds by light microscopy, and the chemotactic activity
was expressed as the net percentage. *P6 0.05.
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brane-proximal cleavage site [4]. Regarding the shedding
mechanism, a plasma membrane enzyme responsible for the
shedding of TNF-K, i.e. TACE, was also shown to cleave
transforming growth factor-K, TNF-K receptor types I and
II [28,29], the receptors for IL-6, colony-stimulating factor-1
[30,31] and L-selectin [32], and IL-1 type II decoy receptor
[33]. Indeed, Garton et al. demonstrated that sFKN can be
generated by TACE-dependent cleavage and ectodomain
shedding [34].
We also demonstrated monocyte chemotactic activity in the
culture supernatant of the ¢broblasts stimulated with TNF-K
and IL-4. Anti-CX3CR1 neutralizing Ab inhibited approxi-
mately 50% of this activity. This result indicates that about
half of the monocyte chemotactic activity in the supernatant is
sFKN. The above results lead us to hypothesize that the ¢-
broblasts stimulated by these cytokines may accumulate im-
munocompetent cells expressing CX3CR1 at in£ammatory
sites.
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